Skip to content

A Prospective Clinical Study for Evaluation of Safe Resection Margin in Breast Conserving Surgery in Breast Cancer

A Prospective Clinical Study for Evaluation of Safe Resection Margin in Breast Conserving Surgery

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02817334
Enrollment
149
Registered
2016-06-29
Start date
2016-03-31
Completion date
2016-12-31
Last updated
2016-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Near-infrared fluorescence, Indocyanine green, ICG, breast cancer

Brief summary

Near-infrared (NIR) fluorescence imaging using indocyanine green (ICG) has been used for breast cancer surgery such as sentinel lymph node (SLN) mapping and breast cancer localization. In this study, our hypothesis are as following: 1. As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome. 2. indocyanine green (ICG) permitted accurate preoperative and intraoperative detection of the SLNs as well as nonpalpable benign brest lesion in patients with breast cancer.

Detailed description

Indocyanine green, ICG (ICG-fluorescence) * ICG is the most commonly used fluorophore which approve by FDA. * NIR-F imaging with ICG could be used in various surgeries. For example, SLN mapping in breast cancer and localization of liver metastasis, especially superficial lesion * Contains sodium iodide, patients who have history of allergy to iodides should be used as caution. Nonpalpable benign brest lesion localization * New method for the localization and resection of non-palpable breast lesions. * The breast lesion was correctly localized, and the area of ICG corresponded well to the site of the lesions.

Interventions

DRUGindocyanine green

As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome.

Sponsors

National Cancer Center, Korea
Lead SponsorOTHER_GOV

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* nonpalpable breast tumor \< 5cm in patients with breast cancer. * consented patients with more than 18 years * Eastern Cooperative Oncology Group Performance status 0 or 1 * patients who need breast biopsy as treatment for breast cancer.

Exclusion criteria

* nonpalpable breast tumor ≥ 5cm in patients with breast cancer. * inflammatory cancer of breast or patients who need MRM * pregnancy * history of severe allergy to ICG(Indocyanine Green) * iode hypersensitiveness

Design outcomes

Primary

MeasureTime frameDescription
detection rateone dayafter complete resection with intraoperative ultrasound confirmed the lesion

Secondary

MeasureTime frameDescription
determine the pathological stabilityone daydetermine the pathological stability with biopsy results confirmed during surgery

Other

MeasureTime frameDescription
Side effects and availability Side effects and availability Side effects and availability side effects and availabilityfollowing up a week to 3 monthItchiness, erythema, rash and other allergic reactions there could have shots later. Itchiness, erythema, rash and other allergic reactions there could have shots later. Itchiness, erythema, rash and other allergic reactions there could have shots later. Itchiness, erythema, rash and other allergic reactions there could have shots later.
side effects and availabilityfollowing up a week to 3 monthAfter scanning, difficulty breathing, a decrease in blood pressure checked whether he had o reaction, such as anaphylactic shock.
side effects ans availabilityfollowing up a week to 3 monthThe skin discoloration, verify that there aren't stay in a follow-up after three months after surgery.

Countries

South Korea

Contacts

Primary ContactSo-Youn Jung
goje1@ncc.re.kr+82-31-920-1681

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026